The efficacy of the submucosal injection of lidocaine during endoscopic submucosal dissection for colorectal neoplasms: a multicenter randomized controlled study

Masami Ijiri1 · Takahiro Sasaki1 · Mikihiro Fujiya1 · Takuya Iwama1 · Yuki Murakami1 · Keitaro Takahashi1 · Kazuyuki Tanaka2 · Katsuyoshi Ando1 · Nobuhiro Ueno1 · Shin Kashima1 · Kentaro Morichi1 · Hiroki Tanabe1 · Yusuke Saito2 · Toshikatsu Okumura1

Received: 16 April 2020 / Accepted: 16 September 2020 / Published online: 28 September 2020
© The Author(s) 2020

Abstract

Background Endoscopic submucosal dissection (ESD) is currently a common procedure although it requires a long procedural time. We conducted a prospective study to determine the efficacy and safety of lidocaine injection for shortening the procedural time and relieving bowel peristalsis during ESD.

Methods A multicenter randomized controlled study was conducted in three hospitals. Ninety-one patients who underwent colorectal ESD were enrolled. Patients were randomly divided into two groups using the envelope method: the lidocaine group and saline group. The primary endpoint was the procedural time, and the secondary endpoints were the procedural time in each part of the colon and the grade of bowel peristalsis and the incidence and amounts of antispasmodic drugs use and adverse events.

Results The patients' demographics were not markedly different between the two groups. The mean procedural time in the lidocaine group was not markedly different from that in the saline group. In contrast, at the proximal site, the procedural time in the lidocaine group (57 min) was significantly shorter in the saline group (80 min). The grade of bowel peristalsis in the lidocaine group (0.67) was significantly lower than in the saline group (1.17). Antispasmodic drug use was significantly rarer in the lidocaine group than in the saline group. The incidence of adverse events was not markedly different between the two groups.

Conclusions Local lidocaine injection is a feasible option for preventing bowel peristalsis, particularly in the proximal colon, leading to a reduced procedural time for ESD and decreased antispasmodic drug use.

University Hospital Medical Information Network Center (UMIN number: 000022843).
that drug carries risks of inducing hyperglycemia and late-onset hypoglycemia [8]. For these reasons, the administrable amounts of these drugs are limited, particularly in elderly patients or patients with such comorbidities.

Lidocaine is a local analgesic that has long been in use, and its safety in appropriate amounts has been established. The safety of local lidocaine injection during ESD in patients with gastric cancer has recently been proposed [9], and the efficacy of lidocaine spraying during colonoscopy has also been reported [10]. However, the efficacy and safety of lidocaine injection during ESD in patients with colorectal cancer has not yet been explored.

We conducted a multicenter randomized control study to determine the efficacy and safety of lidocaine injection during ESD for the treatment of colorectal T1 cancer.

**Methods**

**Study design and ethical considerations**

This is a multicenter randomized non-blinded control study that was approved by the Ethics Committees of Asahikawa Medical University (15089-3) and other participating institutes and registered with the University Hospital Medical Information Network Center (UMIN number: 000022843). Written informed consent was obtained from all patients enrolled.

**Participants**

From November 2015 to March 2019, 91 patients diagnosed with colorectal adenomas, T1 cancers, or neuroendocrine tumors that were indicated for ESD were enrolled in this study. The exclusion criteria were as follows: patients with severe cardiac disease, severe renal disease, severe cardiac infectious disease, severe diabetes, severe dehydration or malnutrition, and hemorrhagic diathesis as well as those in whom participation was deemed difficult by physician and those < 16 years old.

**Randomization**

The envelope method was used for randomization. Before ESD, patients were divided into two groups at a 1:1 ratio: the lidocaine group and the saline (placebo) group.

**Procedures**

Colonoscopy was started with sedation of 5–10 mg midazolam with no scopolamine butylbromide and/or glucagon. During the insertion of the colonoscope, 20 mg scopolamine butylbromide and/or 1 mg glucagon were injected only when the endoscopist called for an injection. Glucagon was used for patients with heart disease, prostate hypertrophy, and glaucoma as well as those ≥ 75 years old, and scopolamine butylbromide was used for all other patients.

On reaching the lesion, 1% lidocaine or saline was injected at both the oral and anal sides of the lesion before starting ESD. After starting ESD, 1% lidocaine or saline was injected every 15 min. A maximum of 20 ml of 1% lidocaine or saline was injected. If ESD could not be successfully completed after injecting ≥ 20 ml of 1% lidocaine or saline, then the procedure was performed without the injection of 1% lidocaine or saline. Scopolamine butylbromide and/or glucagon were injected when the endoscopist considered antispasmodic drugs necessary.

The grade of bowel peristalsis was classified as follows: score 0, no peristalsis; score 1, less peristalsis with no influence for ESD; score 2, mild peristalsis with influence for ESD; score 3, severe peristalsis in which ESD was able to be continued with some treatment.

**Endpoints**

The primary endpoint was the procedural time of ESD. The secondary endpoints were the bowel peristalsis score, amounts of antispasmodic drugs used, safety of lidocaine injection, and procedural time in each location. A subgroup analysis was performed to analyze the differences according to the location (proximal colon which included the cecum and ascending colon or distal colon).

**Statistical analyses**

The IBM SPSS statistics software program, version 25, was used for the statistical analysis. A t-test or Mann–Whitney U-test was used for the analysis of continuous variables. The Chi-square test or Fisher’s exact test was for nominal variables. P values of less than 0.05 were judged to indicate significance.

**Results**

**Demographics of enrolled patients**

Ninety-one patients were enrolled in this prospective study. These patients were randomly divided into the lidocaine group (n = 54) and saline group (n = 37) using the envelop method. One patient in whom sedation did not work and 2 in whom ESD was not completed due to severe fibrosis were excluded from this study, leaving 51 patients in the lidocaine group and 37 in the saline group for the analysis (Fig. 1). The age, gender, comorbidities, lesion location, histological type, invasion depth, tumor size, and grade of histological
fibrosis were not markedly different between the lidocaine and saline groups (Table 1).

**Primary endpoints**

The median procedural time in the lidocaine group (62 min) was similar to that in the saline group (69 min). No significant difference in the procedural time was observed between the groups (Fig. 2).

**Secondary endpoints**

The median procedural time in the lidocaine group for removing tumors in the proximal colon (57 min), which included the cecum and ascending colon, was significantly shorter than that in the saline group ($p = 0.05$), while no marked differences in the procedural time were observed between the groups in the distal colon, which included the transverse colon, descending colon, sigmoid colon, and rectum (Fig. 3). The bowel peristalsis score of the lidocaine group (0.67) was significantly lower than that of the saline group ($p < 0.05$) (Fig. 4). The median bowel peristalsis score of the lidocaine group in the proximal colon was significantly lower than that in the saline group ($p < 0.01$), and the median bowel peristalsis score in the distal colon of the lidocaine group was significantly lower than that in the distal colon of the saline group ($p = 0.01$) (Fig. 5). The rate of using additional antispasmodic drugs in the lidocaine group (6%) was significantly lower than that in the saline group (35%) ($p < 0.05$) (Table 2). The incidence of adverse events, including perforation, penetration, bleeding, hypotension, bradycardia, tachycardia, and hypoxemia, was similar between the groups (Table 3).

**Table 1 Patients’ demographics**

|                          | Lidocaine group ($n = 51$) | Saline group ($n = 37$) | $P$ value |
|--------------------------|-----------------------------|-------------------------|-----------|
| Sex (male: female)       | 30:21:00                    | 19:18                   | $P = 0.32$|
| Age (mean ± SD)          | 69.2 ± 11.9                 | 70.8 ± 8.2              | $P = 0.60$|
| Comorbidities            | 20 (39%)                    | 14 (38%)                | $P = 0.54$|
| Location                 |                             |                         |           |
| Proximal colon:distal colon | 19:32                     | 17:20                   | $P = 0.27$|
| Histological type        |                             |                         |           |
| Adenoma:carcinoma:NET    | 30:19:02                    | 22:14:01                | $P = 0.95$|
| Invasion depth           |                             |                         |           |
| M:SM                     | 15:06                       | 9:05                    | $P = 0.47$|
| Tumor size(mm)           | 20 (20, 30)                 | 25 (20, 40)             | $P = 0.39$|
| Proximal colon           | 25 (20, 30)                 | 30 (20, 42.5)           | $P = 0.10$|
| Distal colon             | 22.5 (13.75, 30)            | 20 (20, 30)             | $P = 0.62$|
| Median(Q1, Q3)           | 9 (18%)                     | 5 (14%)                 | $P = 0.41$|
| Fibrosis                 |                             |                         |           |
Discussion

While the safety of local lidocaine injection in gastric ESD has been proposed [5], the present prospective study investigated the efficacy and safety of local lidocaine injection in colorectal tumors for the first time, illustrating that local lidocaine injection prevented bowel peristalsis during ESD and shortened the procedural time in the proximal colon. The study also showed the high safety of local lidocaine injection, suggesting the usefulness of local lidocaine injection for efficient and safe ESD.

Submucosal fibrosis, difficulties maintaining the scope position, and bowel peristalsis are known to underlie the long procedural time of ESD [2–4]. A number of new cutting devices have been developed for easily cutting submucosal fibrosis. In addition, traction devices, such as the S–O clip [5], as well as the balloon overtube-guided technique [6] and pocket-creation methods [7] have been used to maintain a good endoscopic view. However, few procedures for controlling bowel peristalsis have been developed. While spraying lidocaine has been proposed as a potential procedure for controlling bowel peristalsis, there is no established procedure that can be applied for the minutes-long slowing of peristalsis. The present study proposed for the first time the feasibility of a local lidocaine injection when applied for minutes-long slowing of peristalsis. The combination of new cutting devices, traction devices, and local lidocaine injection may be suitable when performing ESD in difficult cases with large-sized colorectal tumors, submucosal fibrosis, and/or a poor endoscopic view.

ESD at the hepatic and splenic flexures has been considered difficult [11, 12]. Operating an endoscope at the proximal colon has been recognized as more difficult in comparison to the distal colon due to the presence of numerous high semilunar folds and the long scope insertion. In the present study, the procedural time in the proximal colon in the lidocaine group was significantly shorter than that in the saline group, while the procedural time in the distal colon was not markedly different between the two groups, suggesting that relief of the bowel peristalsis might contribute to the shortening of the procedural time.
Based on the results, local lidocaine injection is thought to be recommended for removing colorectal tumors, particularly those in the proximal colon. Antispasmodic drug use was significantly rarer in the lidocaine group than in the saline group, although the procedural time was not markedly different between the two groups. When avoiding antispasmodic drug use during ESD in high-risk cases, such as older patients and/or those with severe comorbidities, local lidocaine injection is recommended even in the distal colon.

Lidocaine blocks the sodium channel and decreases the entry of sodium into neuron cells, thereby inhibiting the activities of both sensory and motor nerves [13]. While it is not clear why lidocaine inhibited bowel peristalsis, we assumed that lidocaine decreased the sensitivity of the mucosal surface, leading to the stimulation of bowel peristalsis by factors in the intestinal lumen. Another possibility was that the submucosal injection of lidocaine directly suppressed the nerve plexus.

Two limitations associated with this study warrant mention. First, this study was blinded for patients but not for endoscopists, which might have influenced the results, including the procedural time and amount of antispasmodic drugs used. Second, the study did not optimize the amount or interval of lidocaine injection. Further double-blinded studies are therefore needed in order to clarify the appropriate amount and interval of lidocaine injection for preventing bowel peristalsis during colorectal ESD.

### Table 2  Amount and incidence of antispasmodic drug use

|                          | Lidocaine group (n = 51) | Saline group (n = 37) | P value |
|--------------------------|--------------------------|-----------------------|---------|
| Total volume (ml)        | 8 (6, 12)                | 10 (6, 15)            | P = 0.17|
| Cases using additional antispasmodic agents | n = 3 (6%) | n = 13 (35%) | P = 0.001 |
| Butyl scopolamine bromide | n = 1                    | n = 4                 |         |
| Glucagon                 | n = 2                    | n = 9                 |         |

### Table 3  Adverse events

|                          | Lidocaine group (n = 51) | Saline group (n = 37) | P value |
|--------------------------|--------------------------|-----------------------|---------|
| Minor perforation*       | 4 (8%)                   | 1 (3%)                | P = 0.30|
| Perforation**            | 0 (0%)                   | 2 (5%)                | P = 0.17|
| Bleeding                 | 2 (4%)                   | 2 (5%)                | P = 0.56|
| Hypotension              | 1 (2%)                   | 1 (3%)                | P = 0.67|
| Tachycardia              | 1 (2%)                   | 0 (0%)                | P = 0.58|
| Bradycardia              | 0 (0%)                   | 2 (5%)                | P = 0.17|
| Decrease of SpO2         | 1 (2%)                   | 0 (0%)                | P = 0.58|

*Cases with suspected perforation during ESD without any symptoms associated with the perforation

**Cases with perforation with obvious clinical symptom associated with the perforation

in the proximal colon. Based on the results, local lidocaine injection is thought to be recommended for removing colorectal tumors, particularly those in the proximal colon. Antispasmodic drug use was significantly rarer in the lidocaine group than in the saline group, although the procedural time was not markedly different between the proximal and distal sites of the colon. In the proximal colon, the mean bowel peristalsis scores in the lidocaine and saline groups were 0.67 and 1.25, respectively. The bowel peristalsis scores in the lidocaine group were significantly lower than in the saline group (p < 0.01). In the distal colon, the mean bowel peristalsis scores in the lidocaine and saline groups were 0.61 and 1.00, respectively. The bowel peristalsis scores in the lidocaine group were significantly lower than in the saline group (p = 0.01).

![Fig. 5  Bowel peristalsis scores at the proximal and distal sites of the colon. In the proximal colon, the mean bowel peristalsis scores in the lidocaine and saline groups were 0.67 and 1.25, respectively. The bowel peristalsis scores in the lidocaine group were significantly lower than in the saline group (p < 0.01). In the distal colon, the mean bowel peristalsis scores in the lidocaine and saline groups were 0.61 and 1.00, respectively. The bowel peristalsis scores in the lidocaine group were significantly lower than in the saline group (p = 0.01).](image-url)
In conclusion, local lidocaine injection is a feasible option for preventing bowel peristalsis, particularly in the proximal colon, thereby reducing the ESD procedural time and anti-spasmodic drug use.

Author contributions MI and TS and MF provided major input into the conceptual development of the studies, wrote the manuscript and supervised all of the investigations. TI, AS, TD, YM, TK, KT, KA, NU, SK, and MT managed and treated the enrolled patients and collected and analyzed the data. KT, KM, HT, YS and TO helped design the studies, interpret the data, and prepare/review the manuscript. All of the authors read and approved the final manuscript.

Compliance with ethical standards

Disclosure statement Dr. Fujiya reports grants and personal fees from EA Pharma Co., Ltd., personal fees from Sanofi K.K., personal fees from OLYNPUS Co., Ltd., during the conduct of the study; grants from Kamui Pharma, Inc., grants from Fuji Chemical Industries Co., Ltd., grants and personal fees from AYUMI Pharmaceutical Corporation, grants from JIMRO Co., Ltd., grants from Nobelpharma Co., Ltd., grants and personal fees from Takeda Pharmaceutical Company Limited, grants and personal fees from Nippon Kayaku Co., Ltd., grants and personal fees from AbbVie Inc, grants and personal fees from EA Pharma Co., Ltd., grants and personal fees from Mitsubishi Tanabe Pharma Corporation, grants and personal fees from Janssen Pharmaceutical K.K., grants and personal fees from Pfizer Inc, grants and personal fees from Bristol-Myers Squibb Company, grants and personal fees from KYORIN Pharmaceutical Co., Ltd., grants and personal fees from Daiichi Sankyo Company, Limited, grants from Yakult Honsha Co., Ltd., grants and personal fees from MOCHIDA PHARMACEUTICAL Co., Ltd., grants and personal fees from ZERIA Pharmaceutical Co., Ltd., personal fees from Horii Pharmaceutical Ind., Ltd., personal fees from Sanofi K.K., personal fees from OLYNPUS Co., Ltd., personal fees from Celltrion Healthcare Japan Co., Ltd., personal fees from Medical Tribune Inc., personal fees from AstraZeneca.co.jp, personal fees from Nobelpharma Co., Ltd., personal fees from TAIHO Pharmaceutical Co., Ltd., personal fees from Technical Information Institute Co., Ltd., personal fees from Boehringer Ingelheim GmbH, personal fees from SHIONOGI & Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from TEIJIN PHARMA LIMITED, personal fees from Aspen Japan K.K., personal fees from Kissei Pharmaceutical Co., Ltd., outside the submitted work. Dr. Okumura reports grants from JA Hokkaido Kousei Agricultural Cooperative Association during the conduct of the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in

the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Yamamoto K, Michida T, Nishida T, Hayashi S et al (2015) Colorectal endoscopic submucosal dissection: recent technical advances for safe and successful procedures. World J Gastrointest Endosc 7:1114–1128
2. Marshall JB, Patel M, Mahajan RJ et al (1999) Benefit of intravenous antispasmodic (hyoscine butylbromide) as prophylaxis for colonoscopy. Gastrointest Endosc 49(6):720–726
3. Kim ES, Cho KB, Park KS et al (2011) Factors predictive of perforation during endoscopic submucosal dissection for the treatment of colorectal tumors. Endoscopy 43:573–578
4. Hayashi Y, Miura Y, Yamamoto H (2015) Pocket-creation method for the safe, reliable, and efficient endoscopic submucosal dissection of colorectal lateral spreading tumors. Dig Endosc 27:534–535
5. Ritsuno H, Sakamoto N, Osada T et al (2014) Prospective clinical trial of traction device-assisted endoscopic submucosal dissection of large superficial colorectal tumors using the S-O clip. Surg Endosc 28(11):3143–3149. https://doi.org/10.1007/s00464-014-3572-0
6. Ohta Y, Ohata K, Sumiyama K et al (2009) Balloon overture-guided colorectal endoscopic submucosal dissection. World J Gastrointestol 28(15):6086–6090. https://doi.org/10.3748/wjg.v15.i15.6086
7. Yoshida N, Naito Y, Yasuda R et al (2018) The efficacy of the pocket-creation method for cases with severe fibrosis in colorectal endoscopic submucosal dissection. Endosc Int Open 6(8):E975–E983. https://doi.org/10.1055/a-0593-5818
8. Sanagappalli S, Agnihotri K, Leong R et al (2017) Antispasmodic drugs in colonoscopy: a review of their pharmacology, safety and efficacy in improving polyp detection and related outcomes. Therap Adv Gastroenterol 10(1):101–113
9. Kiriyama S, Oda I, Nishimoto F et al (2009) Pilot study to assess the safety of local lidocaine injections during endoscopic submucosal dissection for early gastric cancer. Gastric Cancer 12(3):142–147
10. Nemoto D, Suzuki S, Mori H et al (2019) Inhibitory effect of lidocaine on colonic spasm during colonoscopy: a multicenter double-blind, randomized controlled trial. Dig Endosc 31(2):173–179
11. He Y, Wang X, Du Y et al (2016) Predictive factors for technically difficult endoscopic submucosal dissection in large colorectal tumors. Turk J Gastroenterol 27(6):541–546
12. Matsumoto S, Uehara T, Mashima H (2019) Construction of a predictive scoring system to predict the difficulty level of colorectal endoscopic submucosal dissection. PLoS One 14(6):e0219096
13. Scholz A (2002) Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth 89(1):52–61